Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Non Operating Income (2016 - 2026)

Aytu Biopharma has reported Non Operating Income over the past 15 years, most recently at $190000.0 for Q4 2025.

  • Quarterly Non Operating Income rose 35.71% to $190000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, up 98.05% year-over-year, with the annual reading at -$512000.0 for FY2025, 158.85% down from the prior year.
  • Non Operating Income was $190000.0 for Q4 2025 at Aytu Biopharma, down from $201000.0 in the prior quarter.
  • Over five years, Non Operating Income peaked at $3.7 million in Q2 2023 and troughed at -$1.2 million in Q4 2022.
  • The 5-year median for Non Operating Income is $120000.0 (2024), against an average of $211157.9.
  • Year-over-year, Non Operating Income crashed 1034.62% in 2023 and then soared 983.33% in 2025.
  • A 5-year view of Non Operating Income shows it stood at -$257000.0 in 2021, then plummeted by 377.82% to -$1.2 million in 2022, then surged by 107.82% to $96000.0 in 2023, then surged by 45.83% to $140000.0 in 2024, then soared by 35.71% to $190000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Non Operating Income are $190000.0 (Q4 2025), $201000.0 (Q3 2025), and $1.3 million (Q2 2025).